Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pruritus as the First Clue: Early Diagnostic Workup Uncovering an Ampullary Adenoma.

Cureus·2026

Same author

Urologist and radiologist contributions to variation in prostate cancer detection at fusion biopsy.

BJU international·2026

Same author

Post-cholecystectomy Choleperitoneum Due to Cystic Duct Stump Leak: A Case Report Emphasizing Diagnostic Challenges and Multidisciplinary Management.

Cureus·2026

Same author

MRI-based predictors of treatment failure in intermediate-risk prostate cancer treated with high-dose-rate brachytherapy as monotherapy.

Brachytherapy·2025

Same author

Analysis of the surgical waiting list for conditions not covered by the Explicit Health Guarantees in orthopedics and traumatology in Chile.

Medwave·2025

Same author

Observational study of the profile of patients undergoing hip and knee arthroplasty in Chilean public hospitals funded through Diagnosis-Related Groups, from 2019 to 2023.

Medwave·2025

Search research articles

Related Experiment Video

Updated: Aug 1, 2025

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

Positive Impact of Implementing a Comprehensive Genetic Testing Protocol for Prostate Cancer Patients in a

Siddharth Ramanathan^1,2, Andrew Korman², Sadhna Ramanathan²

¹Oakland University William Beaumont School of Medicine, Rochester, Michigan.

Urology Practice

|April 27, 2023

Summary

Implementing on-site genetic testing for prostate cancer significantly boosted patient compliance from 33.3% to 98.7%. This streamlined approach also reduced the time to receive genetic test results by 17 days, improving cancer care.

Keywords:

compliance genetic testing prostatic neoplasms workflow

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Related Experiment Videos

Last Updated: Aug 1, 2025

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Area of Science:

Urology
Oncology
Genetics

Background:

Genetic testing for prostate cancer evolved from National Comprehensive Cancer Network (NCCN) guidelines to the 2019 Philadelphia Consensus Conference guidelines.
The updated guidelines support point-of-care genetic testing and genetic counseling.
Limited data exist on the successful implementation of streamlined genetic testing processes.

Purpose of the Study:

To explore the benefits of implementing an on-site, guideline-based genetic testing process for prostate cancer patients.
To assess the impact of guideline-based, on-site genetic testing on compliance and turnaround time.

Main Methods:

Retrospective review of 552 prostate cancer patients from January 2017.
Comparison of genetic testing compliance and turnaround time before and after September 2018.
Pre-September 2018: NCCN guidelines, off-site swab procurement (n=78).
Post-September 2018: Philadelphia Consensus Conference guidelines, on-site swab procurement (n=474).

Main Results:

Genetic testing compliance increased significantly from 33.3% to 98.7% after implementing on-site, guideline-based testing.
The average time to receive genetic test results decreased from 38 days to 21 days, a reduction of 17 days.

Conclusions:

On-site, guideline-based genetic testing significantly improves prostate cancer testing compliance and reduces result turnaround time.
This model enhances the detection of actionable mutations and increases the use of targeted therapies in prostate cancer management.